AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39368459 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT-Video
Number of subjects: 57
Study 39368474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study 39368488 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec (icodec) with a dosing guide app
Number of subjects: 0
Study 39368488 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec (icodec)
Number of subjects: 0
Study 39368488 — intervention group
Group type: COMPARATOR
Intervention: Once-daily basal insulin
Number of subjects: 0
Study 39368797 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 807
Study 39368841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepiapterin
Number of subjects: 157
Study 39368841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 39368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional competence app
Number of subjects: 2532
Study 39368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) app
Number of subjects: 2532
Study 39368870 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring app
Number of subjects: 2532
Study 39368870 — intervention group
Group type: COMPARATOR
Intervention: All groups (emotional competence app, CBT app, self-monitoring app)
Number of subjects: 2532
Study 39368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) self-help app
Number of subjects: 1262
Study 39368871 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional competence self-help app
Number of subjects: 1262
Study 39368871 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring app
Number of subjects: 1262
Study 39368878 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with high-dose cytarabine (HDAC)
Number of subjects: 121
Study 39368878 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg adult-equivalent
Number of subjects: 121
Study 39368878 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 121
Study 39368973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant fulvestrant with enzalutamide (Combo)
Number of subjects: 59
Study 39368973 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant fulvestrant (Fulv)
Number of subjects: 59
Study 39369129 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-therapy > 2 years
Number of subjects: 1627
Study 39369129 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-therapy > 2 years in low-risk subgroup
Number of subjects: 1627
Study 39369231 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 40
Study 39369231 — intervention group
Group type: COMPARATOR
Intervention: X-ray radiotherapy
Number of subjects: 40
Study 39369239 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session telephone-delivered behavioural activation treatment as an add-on to treatment as usual
Number of subjects: 250
Study 39369239 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual in primary care
Number of subjects: 250
Study 39369249 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation induction
Number of subjects: 326
Study 39369249 — intervention group
Group type: COMPARATOR
Intervention: Intravenous induction
Number of subjects: 326
Study 39369275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary quality (measured by AHEI-2010)
Number of subjects: 132
Study 39369275 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of red and processed meat
Number of subjects: 132
Study 39369275 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 132
Study 39369275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 132
Study 39369582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological ascorbate (P-AscH)
Number of subjects: 0
Study 39369582 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) with gemcitabine and nab-paclitaxel
Number of subjects: 0
Study 39369790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with or without chemotherapy
Number of subjects: 637
Study 39369790 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 637
Study 39369987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lung ultrasound score (LUS) ≥8
Number of subjects: 877
Study 39369987 — intervention group
Group type: COMPARATOR
Intervention: Revised Cardiac Risk Index (RCRI) scores
Number of subjects: 877
Study 39369987 — intervention group
Group type: COMPARATOR
Intervention: National Surgical Quality Improvement Program Myocardial infarction and Cardiac arrest (NSQIP-MICA) scores
Number of subjects: 877
Study 39369987 — intervention group
Group type: COMPARATOR
Intervention: American Society of Anesthesiologists Physical Status (ASA-PS) classes
Number of subjects: 877
Study 39369987 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lung ultrasound score (LUS)
Number of subjects: 877
Study 39370144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for 48 weeks
Number of subjects: 10
Study 39370775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 489
Study 39370868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 1 (RM1) - n=66
Number of subjects: 519
Study 39370868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 2 (RM2) - n=84
Number of subjects: 519
Study 39370868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 3 (RM3) - n=64
Number of subjects: 519
Study 39370868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 4 (RM4) - n=188
Number of subjects: 519
Study 39370868 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 5 (RM5) - n=119
Number of subjects: 519
Study 39371020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-voltage area ablation (group A)
Number of subjects: 161
Study 39371020 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon-guided left atrial appendage isolation (group B)
Number of subjects: 161
Study 39371104 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus penpulimab
Number of subjects: 21
Study 39371161 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph-based clustering approach to identify temporal segments of speech production from ECoG signals
Number of subjects: 1
Study 39371161 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice activity detection (VAD) model trained using ECoG signals
Number of subjects: 1
Study 39371161 — intervention group
Group type: COMPARATOR
Intervention: Comparison to previous solutions trained with ground truth acoustic voice recordings
Number of subjects: 1
Study 39371165 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g daily of KE (bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30
Study 39371165 — intervention group
Group type: COMPARATOR
Intervention: Taste, appearance, and calorie-matched placebo (PLA) containing canola oil
Number of subjects: 30
Study 39371411 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIFS training model
Number of subjects: 42
Study 39371411 — intervention group
Group type: COMPARATOR
Intervention: Care-as-Usual training
Number of subjects: 42
Study 39372262 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin D (cholecalciferol 50 mcg)
Number of subjects: 64
Study 39372262 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 64
Study 39372369 — intervention group
Group type: EXPERIMENTAL
Intervention: KETO diet (carbohydrate restriction-induced LDL-C ≥190 mg/dL)
Number of subjects: 80
Study 39372369 — intervention group
Group type: COMPARATOR
Intervention: MiHeart controls (lower LDL-C)
Number of subjects: 80
Study 39373062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 139
Study 39373144 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based intervention targeting anger management
Number of subjects: 0
Study 39373144 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Virological Response (SVR) group (n=54)
Number of subjects: 111
Study 39373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Level Viraemia (VLLV) group (n=30)
Number of subjects: 111
Study 39373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasionally Low-Level Viraemia (OLLV) group (n=17)
Number of subjects: 111
Study 39373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Low-Level Viraemia (MLLV) group (n=10)
Number of subjects: 111
Study 39373164 — intervention group
Group type: COMPARATOR
Intervention: Non-VLLV (including MLLV)
Number of subjects: 111
Study 39373164 — intervention group
Group type: COMPARATOR
Intervention: LLV group
Number of subjects: 111
Study 39373173 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT threshold of 15 μg/g
Number of subjects: 47265
Study 39373173 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT threshold of 47 μg/g
Number of subjects: 47265
Study 39373173 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT threshold of 150 μg/g
Number of subjects: 47265
Study 39373173 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection rate of stage I CRC
Number of subjects: 47265
Study 39373173 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-colonoscopy bleeding rates
Number of subjects: 47265
Study 39373311 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1820237 (0.075-2.4 mg)
Number of subjects: 95
Study 39373311 — intervention group
Group type: COMPARATOR
Intervention: BI 1820237 (1.2 mg)
Number of subjects: 95
Study 39373311 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1820237 (0.025-1.2 mg) + liraglutide (0.6 mg)
Number of subjects: 95
Study 39373311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 39373498 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-natal antibiotic exposure
Number of subjects: 30
Study 39373498 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic-naive infants
Number of subjects: 30
Study 39373498 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall presence of antibiotic resistance genes (ARGs)
Number of subjects: 30
Study 39373498 — intervention group
Group type: COMPARATOR
Intervention: Preterm infants without direct or intrapartum antibiotic exposure
Number of subjects: 30
Study 39373766 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive online group programme combining pain neuroscience education (PNE) and graded exposure to movement (GEM) for 12 weeks
Number of subjects: 49
Study 39373766 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study 39373831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hello Bundle intervention (6 components: Hello campaign posters, email reminders, integrating greetings in morning huddles, hello jars, lead-by-example initiatives, daily updated hello board)
Number of subjects: 7300
Study 39373831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hello Bundle intervention
Number of subjects: 7300
Study 39373843 — intervention group
Group type: EXPERIMENTAL
Intervention: STS101 (5.2 mg dihydroergotamine nasal powder)
Number of subjects: 344
Study 39373844 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules) at doses between 200 and 600 mg/day
Number of subjects: 159
Study 39373844 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules) at doses ≥ 400 mg/day
Number of subjects: 159
Study 39373844 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine ER (extended-release capsules)
Number of subjects: 159
Study 39373998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap position (hand supported on lap)
Number of subjects: 133
Study 39373998 — intervention group
Group type: EXPERIMENTAL
Intervention: Side position (arm unsupported at the side)
Number of subjects: 133
Study 39373998 — intervention group
Group type: COMPARATOR
Intervention: Desk position (desk 1; reference)
Number of subjects: 133
Study 39374004 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked taper plus cognitive behavioral therapy-augmented program (MTcap)
Number of subjects: 188
Study 39374004 — intervention group
Group type: COMPARATOR
Intervention: Standard CBTI plus supervised (unmasked) gradual taper (SGT)
Number of subjects: 188
Study 39374016 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS (Community Participation Transition after Stroke) program
Number of subjects: 185
Study 39374016 — intervention group
Group type: COMPARATOR
Intervention: Control group (attentional control)
Number of subjects: 185
Study 39374130 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Assessment and Treatment Program (IATP)
Number of subjects: 0
Study 39374130 — intervention group
Group type: COMPARATOR
Intervention: CaseM
Number of subjects: 0
Study 39374130 — intervention group
Group type: COMPARATOR
Intervention: PCBT
Number of subjects: 0
Study 39374216 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE) supervised by a physiotherapist twice a week for 12 weeks
Number of subjects: 140
Study 39374216 — intervention group
Group type: COMPARATOR
Intervention: Neck-specific exercise with internet support and four physiotherapy visits (NSEIT)
Number of subjects: 140
Study 39374216 — intervention group
Group type: COMPARATOR
Intervention: NSEIT and NSE
Number of subjects: 140
Study 39374319 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=152)
Number of subjects: 300
Study 39374319 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control, n=148)
Number of subjects: 300
Study 39374319 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=151)
Number of subjects: 300
Study 39374319 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control, n=149)
Number of subjects: 300
Study 39374319 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy (n=148)
Number of subjects: 300
Study 39374319 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control, n=146)
Number of subjects: 300
Study 39374480 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapies (MTTs) post-MTB evaluation
Number of subjects: 283
Study 39374480 — intervention group
Group type: EXPERIMENTAL
Intervention: Approved tyrosine kinase inhibitors
Number of subjects: 283
Study 39374480 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy/immunotherapy
Number of subjects: 283
Study 39374480 — intervention group
Group type: COMPARATOR
Intervention: No matched targeted therapy (MTT)
Number of subjects: 283
Study 39374521 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib 80 mg daily plus dasatinib 140 mg daily plus prednisone 60 mg/m2 daily
Number of subjects: 24
Study 39374532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin, 4 mg daily
Number of subjects: 7731
Study 39374532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7731
Study 39374535 — intervention group
Group type: EXPERIMENTAL
Intervention: R-chemo (rituximab-chemotherapy)
Number of subjects: 324
Study 39374535 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 (rituximab-lenalidomide)
Number of subjects: 324
Study 39374535 — intervention group
Group type: COMPARATOR
Intervention: FL20 (20-gene predictor)
Number of subjects: 324
Study 39374535 — intervention group
Group type: COMPARATOR
Intervention: FLcm assay (using FOXP1, LMO2, CD22, and MUM1 antibodies)
Number of subjects: 324
Study 39374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery thoracoscopic wedge resection (ERAS 3-port VATS)
Number of subjects: 150
Study 39374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in FEV1%pre by 1%
Number of subjects: 150
Study 39374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in DLCO%pre by 1%
Number of subjects: 150
Study 39374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional pack-year
Number of subjects: 150
Study 39374548 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 150
Study 39374555 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Intervention (Brief MI) - 15-minute audio mindfulness practice daily from embryo transfer to pregnancy test (total 180-210 minutes)
Number of subjects: 68
Study 39374555 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremely Brief Meditation (EBMI) - Weekly 40-minute sessions with a meditator instructor (total 80 minutes)
Number of subjects: 68
Study 39374555 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 68
Study 39374573 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical hematopoietic stem cell transplantation
Number of subjects: 18
Study 39374601 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 984
Study 39374601 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 984
Study 39374605 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster group (received homologous booster dose at month 18)
Number of subjects: 248
Study 39374605 — intervention group
Group type: COMPARATOR
Intervention: No-booster group (received no booster)
Number of subjects: 248
Study 39374605 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster group
Number of subjects: 248
Study 39374605 — intervention group
Group type: COMPARATOR
Intervention: No-booster group
Number of subjects: 248
Study 39374638 — intervention group
Group type: EXPERIMENTAL
Intervention: Early 3-month direct oral anticoagulant (DOAC) therapy followed by single antiplatelet therapy (experimental arm)
Number of subjects: 324
Study 39374638 — intervention group
Group type: COMPARATOR
Intervention: Lifelong single antiplatelet therapy (standard arm)
Number of subjects: 324
Study 39374788 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intravenous lipid emulsion (CO-ILE) with fish oil
Number of subjects: 161
Study 39374788 — intervention group
Group type: COMPARATOR
Intervention: Pure soybean oil lipid emulsion (SOLE)
Number of subjects: 161
Study 39374788 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-ILE
Number of subjects: 161
Study 39374788 — intervention group
Group type: COMPARATOR
Intervention: SOLE
Number of subjects: 161
Study 39374820 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks
Number of subjects: 33
Study 39374820 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 8 weeks in ME/CFS group
Number of subjects: 33
Study 39375057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-based digital therapeutics for supportive care after gastrectomy
Number of subjects: 39
Study 39375058 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean/tofu consumption
Number of subjects: 5535
Study 39375058 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean paste stew consumption
Number of subjects: 5535
Study 39375058 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent consumption of soybean paste stew (≥5 times/week)
Number of subjects: 5535
Study 39375168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with avutometinib plus defactinib
Number of subjects: 270
Study 39375168 — intervention group
Group type: COMPARATOR
Intervention: Investigator's choice of treatment
Number of subjects: 270
Study 39375173 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 10244
Study 39375179 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (400 mcg) and vitamin B supplementation for 3 months
Number of subjects: 0
Study 39375179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39375184 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported symptom scores combined with a faecal calprotectin (FC) home test
Number of subjects: 0
Study 39375184 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy (gold standard)
Number of subjects: 0
Study 39375281 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1249
Study 39375290 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB+RPV LA
Number of subjects: 670
Study 39375290 — intervention group
Group type: COMPARATOR
Intervention: BIC/FTC/TAF
Number of subjects: 670
Study 39375322 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental awareness-based education
Number of subjects: 110
Study 39375488 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive group (n:30)
Number of subjects: 90
Study 39375488 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative group (n:30)
Number of subjects: 90
Study 39375488 — intervention group
Group type: COMPARATOR
Intervention: Control group (n:30)
Number of subjects: 90
Study 39375517 — intervention group
Group type: EXPERIMENTAL
Intervention: Print materials + loaner iPad device with data plan coverage (n=30)
Number of subjects: 90
Study 39375517 — intervention group
Group type: EXPERIMENTAL
Intervention: Print materials + loaner device + up to six, 15-20-minute motivational interviewing-based coaching calls (n=30)
Number of subjects: 90
Study 39375517 — intervention group
Group type: COMPARATOR
Intervention: Print materials (control, n=30)
Number of subjects: 90
Study 39375627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based social intervention once a week for nine weeks (n=162)
Number of subjects: 319
Study 39375627 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=157)
Number of subjects: 319
Study 39375634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) in infected sockets (group I)
Number of subjects: 26
Study 39375634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular socket therapy (VST) in non-infected sockets (group N)
Number of subjects: 26
Study 39375634 — intervention group
Group type: COMPARATOR
Intervention: Comparison of infected (group I) and non-infected (group N) sockets
Number of subjects: 26
Study 39375710 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-Free Home SafeCare (SFHSC); n=25
Number of subjects: 500
Study 39375710 — intervention group
Group type: COMPARATOR
Intervention: Standard SafeCare (active treatment control); n=25
Number of subjects: 500